Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 7/20 | 0.49 |
| ▸ | CNR1 | P21554 | 6/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765808 | 0.91 | BDKRB1 (0.48) | BDKRB1CNR1CARM1PRMT6MET | |
| SCHEMBL764468 | 0.91 | BDKRB1 (0.48) | BDKRB1CNR1CARM1PRMT6MET | |
| SCHEMBL10121533 | 0.89 | BDKRB1 (0.53) | BDKRB1CNR1 | |
| SCHEMBL12239072 | 0.89 | BDKRB1 (0.51) | BDKRB1CNR1CARM1PRMT6 | |
| SCHEMBL765522 | 0.88 | BDKRB1 (0.50) | BDKRB1CNR1CARM1PRMT6MET | |
| Hydrochloric Acid SCHEMBL2546804 | 0.88 | BDKRB1 (0.49) | BDKRB1CNR1CARM1PRMT6MET | |
| SCHEMBL12239059 | 0.87 | BDKRB1 (0.53) | BDKRB1CNR1KDM1AHDAC1 | |
| SCHEMBL12239073 | 0.86 | BDKRB1 (0.47) | BDKRB1CNR1 | |
| SCHEMBL10121221 | 0.85 | BDKRB1 (0.47) | BDKRB1CNR1MET | |
| SCHEMBL10121264 | 0.85 | BDKRB1 (0.49) | BDKRB1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | BDKRB1 1/4885CNR1 72/4885CARM1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.